Cell Counting Market worth USD14.5 billion by 2025

Cell Counting Market

PUNE, India, 2020-Sep-18 — /EPR Network/ —

According to MarketsandMarkets – [247 Pages Report] The global cell counting market is projected to reach USD 14.5 billion in 2025 from USD 10.4 billion in 2020, at a CAGR of 6.7 % during the forecast period.

The market growth is largely driven by factors such as growing funding for cell-based research, rising incidence of chronic and infectious diseases, growing biotechnology and biopharmaceutical industries, the development of enhanced solutions and improved image analysis, and the growing use of high-throughput flow cytometry and automated hematologyanalyzers. On the other hand, the high cost of cell analysis is expected to hinder market growth to a certain extent.

Cell Counting Market by Product (Instruments (Spectrophotometer, Hemocytometer, Flow Cytometer, HematologyAnalyzers), Consumables (Reagent, Microplate)), Cancer, Stem Cell Research, End User (Pharmaceutical, Hospital, Research) – Global Forecast to 2025

Download a PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=157450728

The medical application segment is expected to grow at the highest CAGR during the forecast period

On the basis of application, the cell counting market is segmented into research, medical, and industrial applications. The medical application segment will grow at the highest CAGR in the cell counting market. Increasing government initiatives in stem cell research and the wide usage of cell counting in research are the major factors driving the growth of the research applications segment during the forecast period.

The hospitals and diagnostic laboratories segment is expected to grow at the highest CAGR during the forecast period

On the basis of end users, the cell counting market is segmented into research institutes, hospitals & diagnostic laboratories, pharmaceutical & biotechnology companies and CROs, and other end users. The hospitals and diagnostic laboratories will grow at the highest CAGR during the forecast period. The high growth of this segment can primarily be attributed to the growing regulatory approvals for cell culture-based vaccines, increasing pharmaceutical R&D expenditure, and commercial expansion of various pharmaceutical companies.

Request a Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=157450728

The Asia Pacific region is expected to account for the largest share of the cell counting market during the forecast period

The APAC region is expected to grow at the highest CAGR during the forecast period. The large growth of this segment can be attributed to factors such as the growing number of proteomics, genomics, and stem cell research activities; increasing research funding; increasing investments by pharmaceutical and biotechnology companies; and the growing trend of research infrastructure modernization.

Key Market Players

The major companies in the cell counting market include Thermo Fisher Scientific Inc (US), Merck KGaA (Germany), PerkinElmer Inc (US), Olympus Corporation (Japan), HORIBA Ltd (Japan), Logos BiosystemsInc (South Korea), Corning Incorporated (US), Tecan Trading AG (Switzerland), Abbott (US), General Electric Company (US), Boule Diagnostics AB (Sweden), Becton, Dickinson and Company (US), Tip Biosystems (Singapore), Agilent Technologies Inc (US), Sysmex Corporation (Japan), Siemens Healthcare Private Limited (Germany), Danaher (US), Diconex (Argentina), Beckman Coulter Inc (US), Nexcelom Bioscience LLC (US), ChemoMetec A/S (Denmark), Bio-Rad Laboratories Inc (US), Advanced Instruments (US), R&D Systems, Inc. (US), and Cole-Parmer Instrument Company LLC (US)

Recent Developments:

  • In 2020, Danaher (US) acquired the Biopharma business of GE Life Sciences, GE Healthcare. This business will be established as a standalone operating company with Danaher’s Life Science segment.
  • In 2019, Agilent Technologies acquired BioTek Instruments, Inc. (US). This acquisition will strengthen Agilent Technologies’ position in the cell counting market.
  • In 2019, Perkin Elmer entered into an agreement with Accenture to join Accenture’s Open Partner Ecosystem Program to help researchers accelerate drug discovery and improve patient outcomes.

Speak to Analyst @ https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=157450728

 

Matched content

Editor’s pick

Do NOT follow this link or you will be banned from the site!